Guangdong Hengrui Pharmaceutical Co., Ltd
Quick facts
Marketed products
Phase 3 pipeline
- HR-1703 · Oncology
HR-1703 is a tyrosine kinase inhibitor that targets specific oncogenic pathways to inhibit tumor cell growth and proliferation. - SHR-1819 · Unknown
SHR-1819 is a small molecule drug that targets the molecular target. - SHR-1905 Injection · Oncology
SHR-1905 Injection is a monoclonal antibody targeting PD-1.
Phase 2 pipeline
- Budesonide inhalant · Respiratory
Glucocorticoid receptor agonist - HRS-2261 oral tablet
- HRS-9813 capsule mimetic
- HRS-9813 capsules
- SHR-1906
- SHR-2173
- SHR4597
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Guangdong Hengrui Pharmaceutical Co., Ltd portfolio CI brief
- Guangdong Hengrui Pharmaceutical Co., Ltd pipeline updates RSS
Frequently asked questions about Guangdong Hengrui Pharmaceutical Co., Ltd
What are Guangdong Hengrui Pharmaceutical Co., Ltd's marketed drugs?
Top marketed products include Moxifloxacin Hydrochloride Tablets.
What is Guangdong Hengrui Pharmaceutical Co., Ltd's pipeline?
Guangdong Hengrui Pharmaceutical Co., Ltd has 3 drugs in Phase 3, 7 in Phase 2, 7 in Phase 1. Late-stage candidates include HR-1703, SHR-1819, SHR-1905 Injection.